Alzinova: Rights issue subscribed to 86.2%
Redeye comments on the final outcome of Alzinova's rights issue. The issue was subscribed to about 86.2% and brings in roughly SEK44m before issue...
88 Views
Alzinova: Encouraging results from Diagnostics study
Redeye comments on Alzinova's announcement that it has completed its research collaboration with Amsterdam UMC within the company's blood-based...
86 Views
Alzinova: Phase II study update and SEK51 rights issue
Redeye comments on Alzinova’s announcements of the operational start-up of the global Phase II study for ALZ-101 and a SEK51m rights issue,...
84 Views
Alzinova (Q2 Review): Capitalizing on diagnostics opportunities
Redeye provides a research update following the Q2 report published by Alzinova earlier today. The financials in the report contained no major...
86 Views
Alzinova: Diagnostics collaboration with Fujirebio
Redeye comments on today’s announcement that Alzinova has signed a non-binding Letter of Intent with Fujirebio regarding the potential development...
89 Views